TY - JOUR
T1 - Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma
T2 - is it useful the application in clinical practice? A pilot study
AU - Fucile, Carmen
AU - Marenco, Simona
AU - Bazzica, Marco
AU - Zuccoli, Maria L aura
AU - Lantieri, Francesca
AU - Robbiano, Luigi
AU - Marini, Valeria
AU - Di Gion, Paola
AU - Pieri, Giulia
AU - Stura, Paola
AU - Martelli, Antonietta
AU - Savarino, Vincenzo
AU - Mattioli, Francesca
AU - Picciotto, Antonino
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Pharmacokinetics and dose-finding studies on sorafenib were conducted on heterogeneous groups of patients with solid tumors. Portal hypertension, gut motility impairment and altered bile enterohepatic circulation may explain different sorafenib toxicological profile in cirrhotic patients. This study evaluated sorafenib plasma concentration in a homogeneous group of cirrhotic patients with hepatocellular carcinoma (HCC). Sorafenib concentrations were determined by liquid chromatography in 12 consecutive patients. Data have been evaluated by the generalized estimating equations method (p value statistical level was set at α = 0.05). (1) There were not significant differences between sorafenib concentrations in patients who tolerate the full dose versus patients with reduced dose due to toxicity; (2) the average sorafenib concentrations measured 3 h after the morning dosing were lower than those measured 12 h after the evening dosing (p = 0.005); (3) sorafenib concentrations decrease overtime (p
AB - Pharmacokinetics and dose-finding studies on sorafenib were conducted on heterogeneous groups of patients with solid tumors. Portal hypertension, gut motility impairment and altered bile enterohepatic circulation may explain different sorafenib toxicological profile in cirrhotic patients. This study evaluated sorafenib plasma concentration in a homogeneous group of cirrhotic patients with hepatocellular carcinoma (HCC). Sorafenib concentrations were determined by liquid chromatography in 12 consecutive patients. Data have been evaluated by the generalized estimating equations method (p value statistical level was set at α = 0.05). (1) There were not significant differences between sorafenib concentrations in patients who tolerate the full dose versus patients with reduced dose due to toxicity; (2) the average sorafenib concentrations measured 3 h after the morning dosing were lower than those measured 12 h after the evening dosing (p = 0.005); (3) sorafenib concentrations decrease overtime (p
UR - http://www.scopus.com/inward/record.url?scp=84931826282&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931826282&partnerID=8YFLogxK
U2 - 10.1007/s12032-014-0335-7
DO - 10.1007/s12032-014-0335-7
M3 - Article
C2 - 25429830
AN - SCOPUS:84919951497
SN - 1357-0560
VL - 32
SP - 335
JO - Medical Oncology
JF - Medical Oncology
IS - 1
ER -